InvestorsHub Logo
Followers 67
Posts 1293
Boards Moderated 0
Alias Born 08/12/2014

Re: meirluc post# 474458

Tuesday, 05/17/2022 9:10:30 AM

Tuesday, May 17, 2022 9:10:30 AM

Post# of 700274
I have explained this in one of my previous post: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=168865226.

Background: the control [edit: treatment] consists of 232 nGBM patients; the control consists of 99 nGBM patients initially, and then 64 patients of the 99 patients who crossed over to receive DCVax-L treatment plus 35 patients who have never been treated with DCVax-L.

It's known that about 30–49% of GBM tissues have been classified as the mesenchymal subtype. Patients with this subtype, both with primary and recurrent tumours, tend to have the worst survival rates compared to other subtypes (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485274/). [Before DCVax-L emerges as the most effective treatment for this group, see below]

The beauty with DCVax-L in treating this subtype of patients is that as Dr. Liau has persistently pointed out over the years, despite the worst prognostication of this type treated with any other treatments available before DCVax-L, it has shown stellar efficacy when treated with DCVax-L [this conclusion can trace back to when Dr. Liau conducted Phase1/2 DCVax-L trial for nGBM more than a decade ago].

Patients from the control (n 64+35) at/after the recurrence those 64 patients have significant higher percentage of the mesenchymal subtype than that of the treatment arm (n 232).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News